JAMA Clinical Reviews

Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: The US Food and Drug Administration's Regulation of Mifepristone Politics, Science, and the Future of FDA Drug Regulation

Incidence rates of gastric cancer in younger individuals are on the rise and gastric cancer is the fifth-leading cause of cancer-related deaths worldwide. JAMA Review author Haeseong Park, MD, MPH, from the Dana Farber Cancer Institute, discusses this and more with JAMA Senior Editor Karen Lasser, MD, MPH. Related Content: Gastric Cancer

JAMA Deputy Editor Mary McDermott, MD, and JAMA Deputy Editor Kristin Walter, MD, MS, highlight their selections of top JAMA Clinical Reviews podcasts in 2025. Related Content: Managing Adverse Effects of Obesity Medications Diagnosis and Management of Hypothyroidism Type 2 Diabetes: Diagnosis and Current Guidelines for Treatment Managing Adverse Effects of Incretin-Based Medications for Obesity Hypothyroidism Diagnosis and Treatment of Type 2 Diabetes in Adults JAMA Editors' Choice 2024: Clinical Reviews Podcasts

In this episode, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Medical News Director Jennifer Abbasi discuss the journal's inaugural Research of the Year roundup. Related Content: Research of the Year 2025

Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease. WHO recently published a guideline in JAMA on the use and indications of GLP-1 therapies for the treatment of #obesity in adults. Francesca Celletti, MD, PhD, and Ezekiel Emanuel, MD, PhD, join JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss. Related Content: World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults